HAVN Life Natural Health Products Now Available on Amazon.com

The Company continues to grow its global retail footprint by partnering with the world's largest ecommerce site

VANCOUVER, BC, Feb. 28, 2022 /CNW/ -  HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life"), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, is pleased to announce that its portfolio of natural health products is now available through Amazon.com. The ecommerce giant carries the full line of HAVN Life's natural health products launched last June, and ships to more than 100 countries around the globe.

"Over the past year, HAVN Life has been steadily working to build a solid foundation for our Retail Division by securing distribution partnerships and making sure our line of natural health products is available through the best possible e-commerce partners," says HAVN Life CEO Tim Moore. "Today, we are so pleased to announce that HAVN Life's suite of products will be sold through Amazon.com - the world's largest ecommerce site. With our growing retail footprint, HAVN Life is solidifying its position as an international supplier of plant-based natural health supplements, bolstering its role as a supply chain leader in the functional mushroom natural health product space." he adds.

The full line includes Rhodiola Relief, Mind Mushroom, Chaga Immunity, Reishi Recharge, Bacopa Brain, Lion's Mane and Cordyceps Perform and is now available through Amazon.com, Amazon.ca and Well.ca, as well as through their HAVN Life's ecommerce site, yourhavnlife.com, which ships products to both US and Canadian customers. The products can also be purchased at Horizon Grocery + Wellness, Choices Market and Nesters Market locations in British Columbia, Canada, as well as at independent specialty retailers across Canada.

HAVN Life's natural health products are expected for introduction to the Australian, New Zealand and Chinese market in 2022 through the Company's distribution partner, Woke Pharmaceuticals. The Sydney-based company has distribution channels through Australian retailers, including major supermarkets and other retail outlets, as well as through various e-commerce portals such as Australia and New Zealand Amazon sites.

HAVN Life formulations are non-GMO, vegan, bioavailable, and naturally-derived from functional mushrooms and other plants and created with human optimization in mind. The natural health product line has been thoughtfully formulated with adaptogens and antioxidants to support overall brain health, with natural compounds that are proven to support memory, focus, energy, and overall cognitive function.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.

HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and cognitive function.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter,  Instagram and Youtube.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business, including the expected introduction of the Company's natural health products to the Australian, New Zealand and Chinese markets in 2022. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the introduction of the Company's natural health products to the Australian, New Zealand and Chinese markets in 2022 will not be completed as expected, or at all, and risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

SOURCE HAVN Life Sciences Inc.

Investor Relations: [email protected] 604 359 0060; Media: [email protected] 647 896 8078